| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
343 |
208 |
$309K |
| J0178 |
Injection, aflibercept, 1 mg |
293 |
205 |
$292K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
540 |
292 |
$221K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
4,958 |
4,446 |
$171K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
4,763 |
4,368 |
$124K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
2,305 |
2,204 |
$81K |
| 92134 |
|
5,729 |
5,248 |
$69K |
| 92250 |
|
3,847 |
3,519 |
$58K |
| J9035 |
Injection, bevacizumab, 10 mg |
1,067 |
642 |
$47K |
| 92235 |
|
949 |
918 |
$31K |
| J3590 |
Unclassified biologics |
50 |
31 |
$14K |
| 92226 |
|
1,757 |
1,198 |
$14K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
215 |
207 |
$13K |
| 92202 |
|
1,035 |
967 |
$5K |
| 92225 |
|
171 |
93 |
$1K |
| J7999 |
Compounded drug, not otherwise classified |
41 |
24 |
$852.93 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
389 |
359 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
115 |
109 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
602 |
564 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
55 |
54 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
27 |
27 |
$0.00 |
| G8952 |
Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given |
40 |
38 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
155 |
152 |
$0.00 |
| 1036F |
|
401 |
371 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
215 |
198 |
$0.00 |